Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. (NYSE: AORT) is a medical device company focused on cardiac and vascular surgery, particularly the treatment of aortic diseases. News about Artivion frequently centers on its aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as clinical and regulatory developments related to these products.
Investors and clinicians following AORT news can expect regular updates on quarterly financial results, including revenue trends for key product lines such as stent grafts, On-X valves, BioGlue surgical sealant and preservation services. Earnings releases often discuss constant currency growth, adjusted EBITDA and non-GAAP performance metrics, along with management’s commentary on business momentum and financial outlook.
Artivion’s news flow also highlights progress in its aortic disease clinical programs. Recent announcements have covered the PERSEVERE and PROTECT trials for the AMDS Hybrid Prosthesis, including late-breaking data presented at major cardiothoracic surgery meetings, as well as the ARTIZEN pivotal trial evaluating the Arcevo LSA Hybrid Stent Graft System for acute and chronic aortic arch pathologies. These updates provide insight into the clinical performance and potential regulatory pathways for the company’s aortic technologies.
Additional news items may include participation in healthcare and medtech investor conferences, amendments to credit facilities, real estate transactions related to manufacturing capacity, and executive leadership changes disclosed through SEC filings and press releases. For market participants tracking AORT, this news page offers a centralized view of Artivion’s financial communications, clinical milestones and corporate developments over time.
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company specializing in aortic disease, has announced the release date for its second quarter 2024 financial results. The results will be made public on Thursday, August 8, 2024, after market close. Following the release, the company will host a teleconference call and live webcast at 4:30 p.m. ET to discuss the results and conduct a Q&A session led by Pat Mackin, Chairman, President and CEO of Artivion.
Interested parties can access the live teleconference by dialing 201-689-8261 shortly before 4:30 p.m. ET. A replay will be available approximately one hour after the event. The live webcast and replay can be accessed through the Investors section of Artivion's website at www.artivion.com.
Artivion has revised its agreements with Endospan, providing up to $25 million in debt financing to assist in obtaining FDA approval for the NEXUS Stent Graft System. The upfront payment for a potential purchase of Endospan has been reduced to $135 million, inclusive of loan offsets, and the $100 million minimum earnout has been eliminated. NEXUS offers a minimally invasive treatment for aortic arch disease, targeting a $600 million annual global market. Artivion retains the option to acquire Endospan within 90 days of NEXUS FDA approval, with terms allowing for up to $12.5 million in equity as part of the payment.
Artivion, Inc. (NYSE: AORT) reported strong first quarter 2024 financial results with revenue of $97.4 million, an increase of 17% on a GAAP basis. Net income was $7.5 million, and non-GAAP adjusted EBITDA increased by 60%. The company revised its FY24 revenue guidance to 9-12% growth. The On-X aortic valve post-market clinical study showed promising results, lowering the risk of major bleeding by 87%. Artivion raised the lower end of its revenue guidance for 2024 and expects non-GAAP adjusted EBITDA to increase by 26-34% compared to 2023.
Artivion, Inc. (NYSE: AORT) announced new clinical data for On-X Aortic Heart Valve and AMDS at the 104th AATS Annual Meeting. 5-year real-world safety and efficacy data from On-X Aortic Valve show better patient outcomes than predicted. AMDS PERSEVERE Trial data demonstrate positive aortic remodeling outcomes. On-X Aortic Valve remains safe with low-dose warfarin. AMDS prevents DANE tears and induces positive aortic remodeling.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.